Meeting
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
Authors
Maro Ohanian
The University of Texas MD Anderson Cancer Center, Houston, TX
Maro Ohanian , Farhad Ravandi , Gautam Borthakur , Guillermo Garcia-Manero , Michael Andreeff , Elias Jabbour , Yesid Alvarado , Marina Konopleva , Miranda Lim , Sherry Pierce , Susan Mary O'Brien , Ana Tari Ashizawa , Srdan Verstovsek , William G. Wierda , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01159028
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7010)
DOI
10.1200/JCO.2016.34.15_suppl.7010
Abstract #
7010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real-world data.
First Author: Taylor J. Jensen
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie
Poster
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
First Author: Justin M. Watts